<p>想投資一些價格低廉且長期潛力巨大的股票嗎？以下列出的股票可能是尋求便宜貨的投資者的絕佳選擇，因為每隻股票的交易價格都低於每股 100 美元，並且被嚴重低估。儘管它們最近的表現並不理想，但從長遠來看，考慮到其低估值，它們可能會帶來可觀的回報。</p>
<p>以下是您為何要考慮投資 <strong>諾和諾德公司</strong>(NVO -4.54%)、<strong>塔吉特</strong>(TGT -1.32%) 和 <strong>輝瑞</strong>(PFE -1.97%) 的原因，儘管它們今年的表現平平。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzQxMTAvc29tZW9uZS1yZXZpZXdpbmctYS1zdG9jay1vbi10aGVpci1jb21wdXRlci5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzQxMTAvc29tZW9uZS1yZXZpZXdpbmctYS1zdG9jay1vbi10aGVpci1jb21wdXRlci5qcGcmdz03MDA"/></p>
<p>圖片來源：Getty Images。</p>
<h2>1. 諾和諾德公司</h2>
<p>丹麥製藥公司諾和諾德在 GLP-1 藥物市場中佔據重要地位，Wegovy（用於減肥）和 Ozempic（用於糖尿病）是其兩款核心產品，為其業務帶來了數十億美元的收入。</p>
<p>由於公司下調了財政年度的業績指引，導致增長速度低於預期，其股價在 7 月底暴跌。諾和諾德一直在努力阻止其熱門藥物的仿製版本進入市場，這兩大挑戰導致其股價今年迄今已下跌近 32%；截至週三收盤，股價僅略低於 59 美元。</p>
<p>儘管股價看起來不太樂觀，但仍有很多理由對其保持樂觀。Wegovy 仍處於增長的早期階段，特別是在其擴展到新市場時。同時，Wegovy 的口服版本看起來前景可期，參與三期臨牀試驗的參與者在 64 周後平均減重 16.6%，與注射版本的表現相符。</p>
<p>這隻醫療股票的市盈率（P/E）僅為 15，考慮到其長期增長潛力，這看起來是個極具吸引力的交易。儘管今年表現不佳，諾和諾德有望反彈。</p>
<h2>2. 塔吉特</h2>
<p>大型零售商塔吉特是另一隻今年表現不佳的股票。其股價下跌近 35%，目前交易價格約為每股 88 美元。今年前六個月的收入總計為 491 億美元，同比下降 2%。消費者在可自由支配支出上有所收縮，這使得公司難以實現收入增長。</p>
<p>這對塔吉特來説是個挑戰：經濟狀況不會迅速好轉，尤其是在消費者面臨因關税而上漲的成本時。然而，今年早些時候，公司宣佈計劃到本世紀末將銷售額增加 150 億美元，專注於其在線市場並提供當日送達服務。</p>
<p>未來面臨挑戰，但該業務並非岌岌可危。過去 12 個月內，它產生了近 30 億美元的自由現金流，財務狀況良好。其市盈率略高於 10，估值極低。您需要對塔吉特保持耐心，但這似乎是一隻被低估的值得購買的股票。</p>
<h2>3. 輝瑞</h2>
<p>本名單的最後一位是另一家頂級醫療公司：輝瑞。截至週三收盤，股價略高於 24 美元，似乎又面臨一個艱難的年度——自 1 月以來下跌了 9%。與 2021 年其 COVID-19 疫苗和治療產品的高峰相比，股價已下跌超過 50%。</p>
<p>增長型投資者對公司的未來感到擔憂，因為它面臨多個專利懸崖，當前的銷售情況也並不強勁。到 2025 年上半年，收入僅增長了 1%，達到 284 億美元。</p>
<p>但輝瑞通過收購不斷擴展其產品線，並最近宣佈計劃以高達 73 億美元收購 GLP-1 藥物製造商 <strong>Metsera</strong>。在 GLP-1 產品方面未能取得成功後，輝瑞希望此次收購能為其在肥胖市場提供強有力的選擇。然而，沒有任何保證：Metsera 尚未產生任何收入，儘管它有一些前景可期的藥物在開發中，但迄今為止沒有任何藥物獲得批准。</p>
<p>輝瑞強勁的財務狀況是投資者不應放棄該股票的原因。儘管增長可能緩慢，但它產生了充足的自由現金流（過去 12 個月為 124 億美元），可以用來幫助追求如 Metsera 及其他公司的收購。並非每一次舉措都會成功，但只需一款有潛力的重磅藥物，就能增強其收入並吸引增長型投資者。</p>
<p>與本名單上的其他股票一樣，輝瑞也存在一定風險。但以 13 的市盈率來看，它是一項便宜的投資，具有良好的安全邊際，可以補償投資者的不確定性。</p>

諾和諾德公司

塔吉特

<p>本文強調了三隻被低估的股票，價格均在 100 美元以下：諾和諾德公司、塔吉特和輝瑞。儘管諾和諾德公司今年下跌了 32%，但在 GLP-1 藥物市場中顯示出長期增長潛力。塔吉特下跌了 35%，計劃通過專注於在線增長來增加 150 億美元的銷售額，當前市盈率低於 10。輝瑞的股價超過 24 美元，面臨挑戰，但財務狀況強勁，並通過收購（包括 Metsera）擴展其產品線。儘管當前面臨困難，每隻股票都為尋求長期收益的投資者提供了買入機會</p>

<p>Want to invest in some low-priced stocks that possess a lot of upside in the long run? The stocks listed below could be great options for bargain hunters, as each one trades at less than $100 per share and is deeply undervalued. While they haven't been doing all that well of late, over the long run, they could generate some terrific returns given their low valuations.</p>
<div class="lb-trans"><p>想投資一些價格低廉且長期潛力巨大的股票嗎？以下列出的股票可能是尋求便宜貨的投資者的絕佳選擇，因為每隻股票的交易價格都低於每股 100 美元，並且被嚴重低估。儘管它們最近的表現並不理想，但從長遠來看，考慮到其低估值，它們可能會帶來可觀的回報。</p>
</div><p>Here's why you'll want to consider putting $100 (or more) toward investments in <strong>Novo Nordisk</strong>(NVO -4.54%), <strong>Target</strong>(TGT -1.32%), and <strong>Pfizer</strong>(PFE -1.97%) despite their lackluster performances this year.</p>
<div class="lb-trans"><p>以下是您為何要考慮投資 <strong>諾和諾德公司</strong>(NVO -4.54%)、<strong>塔吉特</strong>(TGT -1.32%) 和 <strong>輝瑞</strong>(PFE -1.97%) 的原因，儘管它們今年的表現平平。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzQxMTAvc29tZW9uZS1yZXZpZXdpbmctYS1zdG9jay1vbi10aGVpci1jb21wdXRlci5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F834110%2Fsomeone-reviewing-a-stock-on-their-computer.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>1. Novo Nordisk</h2>
<div class="lb-trans"><h2>1. 諾和諾德公司</h2>
</div><p>Danish pharma company Novo Nordisk is a big player in the GLP-1 drug market, with Wegovy (for weight loss) and Ozempic (for diabetes) being two core products that generate billions of dollars in revenue for its business.</p>
<div class="lb-trans"><p>丹麥製藥公司諾和諾德在 GLP-1 藥物市場中佔據重要地位，Wegovy（用於減肥）和 Ozempic（用於糖尿病）是其兩款核心產品，為其業務帶來了數十億美元的收入。</p>
</div><p>Its share price crashed in late July when the company lowered its guidance for the fiscal year, as growth was a bit slower than expected. Novo Nordisk has been fighting a losing battle to keep knockoff compounded versions of its popular drugs off the market. These two headwinds have resulted in the stock price falling close to 32% so far this year; as of Wednesday's close, shares were trading at just under $59.</p>
<div class="lb-trans"><p>由於公司下調了財政年度的業績指引，導致增長速度低於預期，其股價在 7 月底暴跌。諾和諾德一直在努力阻止其熱門藥物的仿製版本進入市場，這兩大挑戰導致其股價今年迄今已下跌近 32%；截至週三收盤，股價僅略低於 59 美元。</p>
</div><p>While the stock looks like it's in bad shape, there's plenty of reason to remain bullish on it. Wegovy is still in the early stages of its growth, particularly as it expands into new markets. Meanwhile, the oral version of Wegovy looks promising, with participants in a phase 3 trial losing an average of 16.6% of their body weight after 64 weeks, which is in line with how the injectable version performs.</p>
<div class="lb-trans"><p>儘管股價看起來不太樂觀，但仍有很多理由對其保持樂觀。Wegovy 仍處於增長的早期階段，特別是在其擴展到新市場時。同時，Wegovy 的口服版本看起來前景可期，參與三期臨牀試驗的參與者在 64 周後平均減重 16.6%，與注射版本的表現相符。</p>
</div><p>The healthcare stock trades at a price-to-earnings (P/E) multiple of only 15, which makes it look like a steal of a deal given its long-term growth potential. While it's not having a great year, Novo Nordisk is likely to rebound.</p>
<div class="lb-trans"><p>這隻醫療股票的市盈率（P/E）僅為 15，考慮到其長期增長潛力，這看起來是個極具吸引力的交易。儘管今年表現不佳，諾和諾德有望反彈。</p>
</div><h2>2. Target</h2>
<div class="lb-trans"><h2>2. 塔吉特</h2>
</div><p>Big-box retailer Target is another stock that has been struggling badly this year. It's down almost 35%, and is currently trading at around $88 per share. Its revenue through the first six months of the year has totaled $49.1 billion, down 2% year over year. Consumers have been pulling back on discretionary spending, and that's made it difficult for the company to grow its top line.</p>
<div class="lb-trans"><p>大型零售商塔吉特是另一隻今年表現不佳的股票。其股價下跌近 35%，目前交易價格約為每股 88 美元。今年前六個月的收入總計為 491 億美元，同比下降 2%。消費者在可自由支配支出上有所收縮，這使得公司難以實現收入增長。</p>
</div><p>It's a challenge for Target: Economic conditions won't make a quick turnaround easy, particularly as consumers battle higher costs due to tariffs. Earlier this year, however, the company announced plans to grow sales by $15 billion by the end of the decade, as it focuses on its online marketplace and offering same-day delivery.</p>
<div class="lb-trans"><p>這對塔吉特來説是個挑戰：經濟狀況不會迅速好轉，尤其是在消費者面臨因關税而上漲的成本時。然而，今年早些時候，公司宣佈計劃到本世紀末將銷售額增加 150 億美元，專注於其在線市場並提供當日送達服務。</p>
</div><p>There are challenges ahead, but the business is by no means in peril. It generated nearly $3 billion in free cash flow over the trailing 12 months and is in solid financial shape. It trades at an incredibly low valuation, with its P/E multiple slightly over 10. You'll need some patience with Target, but this seems like an underrated stock worth buying.</p>
<div class="lb-trans"><p>未來面臨挑戰，但該業務並非岌岌可危。過去 12 個月內，它產生了近 30 億美元的自由現金流，財務狀況良好。其市盈率略高於 10，估值極低。您需要對塔吉特保持耐心，但這似乎是一隻被低估的值得購買的股票。</p>
</div><h2>3. Pfizer</h2>
<div class="lb-trans"><h2>3. 輝瑞</h2>
</div><p>Rounding out this list is another top healthcare company: Pfizer. As of Wednesday's close, the stock was trading at just over $24, and seems on track for another challenging year -- it's down 9% since January. It's also down more than 50% from the highs it reached back in 2021, when its COVID-19 vaccine and treatment were promising products in its portfolio.</p>
<div class="lb-trans"><p>本名單的最後一位是另一家頂級醫療公司：輝瑞。截至週三收盤，股價略高於 24 美元，似乎又面臨一個艱難的年度——自 1 月以來下跌了 9%。與 2021 年其 COVID-19 疫苗和治療產品的高峰相比，股價已下跌超過 50%。</p>
</div><p>Growth investors are concerned about the company's future, as it faces multiple patent cliffs, and its sales today aren't all that strong. Through the first half of 2025, revenue has risen by just 1%, to $28.4 billion.</p>
<div class="lb-trans"><p>增長型投資者對公司的未來感到擔憂，因為它面臨多個專利懸崖，當前的銷售情況也並不強勁。到 2025 年上半年，收入僅增長了 1%，達到 284 億美元。</p>
</div><p>But Pfizer has been expanding its pipeline via acquisitions, and recently announced plans to purchase GLP-1 drugmaker <strong>Metsera</strong> for up to $7.3 billion. After falling short with its GLP-1 products, Pfizer is hoping the acquisition can give it some formidable options in the obesity market. There are no guarantees, however: Metsera isn't generating any revenue yet, and while it has some promising drugs in development, nothing has been approved thus far.</p>
<div class="lb-trans"><p>但輝瑞通過收購不斷擴展其產品線，並最近宣佈計劃以高達 73 億美元收購 GLP-1 藥物製造商 <strong>Metsera</strong>。在 GLP-1 產品方面未能取得成功後，輝瑞希望此次收購能為其在肥胖市場提供強有力的選擇。然而，沒有任何保證：Metsera 尚未產生任何收入，儘管它有一些前景可期的藥物在開發中，但迄今為止沒有任何藥物獲得批准。</p>
</div><p>Pfizer's strong financials are why investors shouldn't give up on the stock. While growth may be sluggish, it generates ample free cash flow ($12.4 billion over the past 12 months), which it can use to help pursue acquisitions such as Metsera and other companies. Not every move will pay off, but all it needs is just one big blockbuster drug that shows promise, which can strengthen its top line and attract growth investors in the process.</p>
<div class="lb-trans"><p>輝瑞強勁的財務狀況是投資者不應放棄該股票的原因。儘管增長可能緩慢，但它產生了充足的自由現金流（過去 12 個月為 124 億美元），可以用來幫助追求如 Metsera 及其他公司的收購。並非每一次舉措都會成功，但只需一款有潛力的重磅藥物，就能增強其收入並吸引增長型投資者。</p>
</div><p>As with the other stocks on this list, there's some risk with Pfizer. But at a P/E of 13, it's a cheap buy that comes with a good margin of safety, which can compensate investors for the uncertainty.</p>
<div class="lb-trans"><p>與本名單上的其他股票一樣，輝瑞也存在一定風險。但以 13 的市盈率來看，它是一項便宜的投資，具有良好的安全邊際，可以補償投資者的不確定性。</p>
</div>

3 只極其便宜的股票，你現在可以以不到 100 美元的價格購買